Medical University of Graz
Division of Endocrinology and Diabetology
Julia Mader, MD Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria Julia Mader is Associate Professor of Medicine at the Division of Endocrinology and Diabetology at the Medical University of Graz, Graz, Austria and is Deputy Head of the Diabetes Outpatient Clinic. She received her medical degree at the Medical University of Graz, where she also trained in Internal Medicine, and Endocrinology and Diabetology. From 2016 to 2017, Prof. Mader was Visiting Professor at the Department of Diabetes, Endocrinology, Clinical Nutrition and Metabolism at the University Hospital of Bern, Bern, Switzerland. She leads the Diabetes Technology Research Unit at the Medical University of Graz. Prof. Mader’s research is focused on diabetes technology with an emphasis on insulin pumps, continuous glucose monitoring, the artificial pancreas and decision support systems. She has published more than 100 peer-reviewed scientific papers and serves as Associate Editor for Frontiers in Clinical Diabetes and Healthcare. Prof. Mader has received several awards in the field of diabetes technology, including the Langerhans award from the Austrian Diabetes Association in 2021. She is a member of several European associations and societies and is a management board member of the Austrian Diabetes Society, within which she heads the Diabetes Education Committee and is a member of the Diabetes Technology Committee. She has authored and co-authored several national guidelines in the field.

Moderator of 1 Session

Session Type
Industry Symposium
Date
Thu, 28.04.2022
Session Time
16:40 - 18:00
Room
Hall 112
Session Description
Treatment and technology together: improving management of type 2 diabetes with a once-weekly insulin - Industry Symposium Supported by Novo Nordisk

Session Description:

IIn this exciting 80-minute session chaired by Dr Julia Mader, the expert faculty will dive into how continuous glucose monitoring (CGM) and once-weekly insulins, treatment and technology united, can address current unmet needs in the management of type 2 diabetes (T2D). Professor Richard Bergenstal will start by discussing evidence and guidelines for use of CGM in clinical trials and day-to-day management of T2D. Dr Mader will introduce once-weekly insulins and present efficacy and safety data and post hoc CGM data from the insulin icodec Phase 2 trials. Finally, Dr Christophe De Block will put the data into clinical context by discussing how CGM and once-weekly insulins can impact future clinical trials, day-to-day clinical practice and patient management. Between plenary sessions, there will be interactive discussions between the experts about future perspectives, such as the insulin icodec Phase 3 programme ONWARDS, and the experts will answer audience questions. The symposium will take place on Thursday 28 April @ 16.40–18.00 CEST.

Presenter of 6 Presentations

What does the future hold?

Session Type
Industry Symposium
Date
Thu, 28.04.2022
Session Time
16:40 - 18:00
Room
Hall 112
Lecture Time
17:30 - 17:40

Q&A

Session Type
Industry Symposium
Date
Thu, 28.04.2022
Session Time
16:40 - 18:00
Room
Hall 112
Lecture Time
17:40 - 17:55

Welcome

Session Type
Industry Symposium
Date
Thu, 28.04.2022
Session Time
16:40 - 18:00
Room
Hall 112
Lecture Time
16:40 - 16:45

Close

Session Type
Industry Symposium
Date
Thu, 28.04.2022
Session Time
16:40 - 18:00
Room
Hall 112
Lecture Time
17:55 - 18:00

What does the future hold?

Session Type
Industry Symposium
Date
Thu, 28.04.2022
Session Time
16:40 - 18:00
Room
Hall 112
Lecture Time
17:00 - 17:05

How once-weekly insulin could simplify diabetes treatment

Session Type
Industry Symposium
Date
Thu, 28.04.2022
Session Time
16:40 - 18:00
Room
Hall 112
Lecture Time
17:05 - 17:20